Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Medicare Must Address High ART Costs, Investigators Argue
April 4th 2022With more people living with HIV now reaching advanced ages and qualifying for Medicare coverage, this new study investigated HIV-related influences on their health care spending, particularly antiretroviral therapy (ART), compared with a population who does not have HIV.
Morbidity, Mortality Improve in HFrEF With Combo Treatment vs Monotherapy
April 2nd 2022This new analysis of data from the Swedish Heart Failure Registry involved an investigation into the relationship between therapy count and dosing on mortality and morbidity among patients with heart failure with reduced ejection fraction (HFrEF).
AstraZeneca’s Camille Hertzka: Olaparib Could Be Practice Changing
April 1st 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why so much excitement has been generated for the use of olaparib (Lynparza) in the first line for patients with metastatic castrate-resistant prostate cancer.
Coffee’s Preventive Benefits for CVD, Heart Disease on Display in Study Pair
March 30th 2022Two studies presented at the annual meeting of the American College of Cardiology show the safety and effectiveness of regular coffee consumption in regard to cardiovascular disease and heart disease, as well as mortality.
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
HIIT Shown to Improve Cardiometabolic Risk in Heart Failure
March 24th 2022This study enrolled 80 middle-aged patients with stage A heart failure and evaluated them for improvements in several cardiovascular and metabolic risk factors through high-intensity interval training (HIIT) for 1 year and omega-3 fatty acid supplementation.
MBC Outcomes Superior With Trastuzumab Deruxtecan vs Trastuzumab Emtansine
March 23rd 2022This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer (mBC) progression following previous treatment failure.
Neutral Findings Predominate German Study of CGM Use
March 22nd 2022This new study from Germany evaluated the use of and satisfaction with continuous glucose monitors (CGMs) since health insurance companies in the country began reimbursement of the technology in 2016 for persons with insulin-dependent diabetes.
HIV-1 Virulence Appears More Potent Among Heterosexual Individuals
March 10th 2022This new study evaluated the influence of transmission bottlenecks on HIV-1 infection virulence by comparing outcomes between penile-vaginal intercourse and anal intercourse, and found more severe disease among heterosexual individuals compared with men who have sex with men.
A DCIS Diagnosis Introduces Physical, Emotional Uncertainty for Many Women
March 10th 2022This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as their concerns over follow-up
Worsened Heart Failure Mortality Seen in Presence of Hyperlactatemia
March 8th 2022A new study of patients receiving care for acute heart failure at Rambam Health Care Campus in Haifa, Israel, investigated how their clinical outcomes might be affected by elevated lactate levels and primary acid-base disorders.
Inadequate Testing for CAD Infuses Heart Failure Space
March 4th 2022This new analysis of commercial and Medicare Advantage claims from all 50 states investigated utilization of and testing trends for coronary artery disease (CAD) among adults aged 18 and older presenting with new-onset heart failure.
AstraZeneca’s Camille Hertzka: Testing for HRR Mutation Status in mCRPC Helps Inform Risk Profile
March 2nd 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with metastatic castrate-resistant prostate cancer (mCRPC).